Abstract
Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Current Molecular Pharmacology
Title:Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency
Volume: 9
Author(s): Yusuke Higuchi, Cu Nguyen, Shin-Ya Yasuda, Michael McMillan, Kouichi Hasegawa and Michael Kahn
Affiliation:
Keywords: p300, CBP, Wnt signaling, peptide mimetics, stem cell, pluripotency.
Abstract: Despite their high degree of identity and even higher homology, the two Kat3 transcriptional coactivators, CBP and p300, have distinct functions, particularly within the Wnt/β-catenin signaling cascade. ICG-001, by directly binding to CBP but not p300, inhibits CBP/β-catenin transcription and has served as an invaluable chemical genomic tool to dissect the Wnt signaling cascade and the divergent roles of these two coactivators. However, to date no direct antagonist of the p300/β-catenin interaction has been reported. We now report the identification and validation of the first highly specific, direct p300/β-catenin antagonists, YH249/250 and their ability to maintain pluripotency in ESC.
Export Options
About this article
Cite this article as:
Higuchi Yusuke, Nguyen Cu, Yasuda Shin-Ya, McMillan Michael, Hasegawa Kouichi and Kahn Michael, Specific Direct Small Molecule p300/β-Catenin Antagonists Maintain Stem Cell Potency, Current Molecular Pharmacology 2016; 9 (3) . https://dx.doi.org/10.2174/1874467208666150526155146
DOI https://dx.doi.org/10.2174/1874467208666150526155146 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic and Amino Acid Alterations of the Tumor Microenvironment
Current Medicinal Chemistry Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer Therapy
Current Cancer Drug Targets Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Enzyme-responsive Nanoparticles for Anticancer Drug Delivery
Current Nanoscience New Improved Drug Delivery Technologies for Pentacyclic Triterpenes: A Review
Protein & Peptide Letters Dextran-based Nanocarriers for Delivery of Bioactives
Current Pharmaceutical Design Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan
Current Drug Delivery Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Prodrugs for Targeted Tumor Therapies: Recent Developments in ADEPT, GDEPT and PMT
Current Pharmaceutical Design Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Use of Fullerenes in Cosmetics
Recent Patents on Biotechnology Diffusion-Weighted Imaging in Abdominal Oncology
Current Medical Imaging Andrographolide Inhibits Proliferation of Colon Cancer SW-480 Cells <i>via</i> Downregulating Notch Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Reconstruction, Topological and Gene Ontology Enrichment Analysis of Cancerous Gene Regulatory Network Modules
Current Bioinformatics Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Characterizing the Functional Similarity of Enzymes with High Co-Citation in Interaction Networks
Protein & Peptide Letters